The expression of CD38 in LCE-multiple myeloma was present but slightly lower than in IGH-multiple myeloma (see Fig. 1B), corresponding with the slightly less (but statistically significant) response to daratumumab ex vivo. This evidence concerns the gene CD38 and AL amyloidosis.